Fabienne Tacchini-Cottier Selected Research

Cutaneous Leishmaniasis

1/2022	The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis.
1/2022	The C5a-C5aR1 complement axis is essential for neutrophil recruitment to draining lymph nodes via high endothelial venules in cutaneous leishmaniasis.
12/2018	Deletion of Interleukin-4 Receptor Alpha-Responsive Keratinocytes in BALB/c Mice Does Not Alter Susceptibility to Cutaneous Leishmaniasis.
1/2018	Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions.
4/2016	The Nlrp3 inflammasome, IL-1β, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice.
1/2012	Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia.
10/2008	Cutaneous leishmaniasis: progress towards a vaccine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabienne Tacchini-Cottier Research Topics

Disease

25	Infections 01/2021 - 09/2002
7	Cutaneous Leishmaniasis 01/2022 - 10/2008
4	Granuloma 05/2013 - 11/2004
3	Leishmaniasis 10/2017 - 10/2008
2	Visceral Leishmaniasis (Kala Azar) 01/2013 - 01/2013
2	Disease Progression 04/2008 - 06/2006
1	Cryptosporidiosis 10/2017
1	Coccidiosis 10/2017
1	Malaria 10/2017
1	Toxoplasmosis 10/2017
1	Colitis 01/2014
1	Shock 01/2014
1	Sepsis (Septicemia) 01/2014
1	HIV Infections (HIV Infection) 01/2013
1	Coinfection 01/2013
1	Tuberculosis (Tuberculoses) 11/2007
1	Necrosis 11/2007
1	Wounds and Injuries (Trauma) 11/2004

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2004
6	Interleukin-4 (Interleukin 4)IBA 10/2020 - 09/2002
5	Messenger RNA (mRNA)IBA 01/2017 - 09/2002
4	CytokinesIBA 01/2021 - 11/2004
3	ArginaseIBA 01/2013 - 01/2012
3	Interleukin-10 (Interleukin 10)IBA 05/2012 - 07/2007
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2008 - 11/2004
2	Pharmaceutical PreparationsIBA 01/2018 - 10/2017
2	Interleukin-12 (IL 12)IBA 05/2014 - 05/2012
2	EndotoxinsIBA 01/2014 - 11/2004
2	AntigensIBA 10/2013 - 01/2012
2	Interferon-gamma (Interferon, gamma)IBA 05/2013 - 09/2003
2	ChemokinesIBA 06/2011 - 02/2010
1	Proto-Oncogene Proteins c-metIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 12/2018
1	Meglumine AntimoniateIBA 01/2018
1	miltefosine (Impavido)IBA 01/2018
1	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 01/2018
1	prolyl T RNA synthetaseIBA 10/2017
1	Caspase 1 (ICE Protease)IBA 04/2016
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 04/2016
1	InflammasomesIBA 04/2016
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2014
1	Dextrans (Dextran)FDA Link 01/2014
1	Peptides (Polypeptides)IBA 01/2014
1	Toll-Like Receptor 9IBA 05/2013
1	EnzymesIBA 01/2013
1	Arginine (L-Arginine)FDA Link 01/2012
1	Pentamidine (NebuPent)FDA LinkGeneric 02/2009
1	DNA VaccinesIBA 10/2008
1	VaccinesIBA 10/2008
1	Immunoglobulin D (IgD)IBA 04/2008
1	Immunoglobulin M (IgM)IBA 04/2008
1	hen egg lysozymeIBA 04/2008
1	Interleukin-23 (Interleukin 23)IBA 11/2007
1	Interleukin-12 Subunit p40IBA 11/2007
1	IntegrinsIBA 08/2007
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2007
1	Interleukin-2 (IL2)IBA 06/2006
1	BCG lipopolysaccharideIBA 11/2004
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2003

Therapy/Procedure

1	Complementary Therapies (Alternative Medicine) 10/2008
1	Therapeutics 10/2008